Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a multi-institutional retrospective cohort study

Abstract

This study aimed to evaluate the efficacy and safety of induction immunochemotherapy followed by definitive chemoradiotherapy (CRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). We identified unresectable stage III NSCLC patients who received induction immunochemotherapy. Overall survival (OS) and progression-free survival (PFS) were the primary endpoints. From February 2019 to August 2022, 158 patients were enrolled. Following the completion of induction immunochemotherapy, the objective response rate (ORR) and disease control rate (DCR) were 52.5% and 83.5%, respectively. The ORR of CRT was 73.5%, representing 68.4% of the total cohort. The median PFS was 17.8 months, and the median OS was 41.9 months, significantly higher than in patients who received CRT alone (p < 0.001). Patients with concurrent CRT demonstrated markedly improved PFS (p = 0.012) and OS (p = 0.017) than those undergoing sequential CRT. Additionally, those with a programmed-death ligand 1 (PD-L1) expression of 50% or higher showed significantly elevated ORRs (72.2% vs. 47.2%, p = 0.011) and superior OS (median 44.8 vs. 28.6 months, p = 0.004) compared to patients with PD-L1 expression below 50%. Hematologic toxicities were the primary severe adverse events (grade ≥ 3) encountered, with no unforeseen treatment-related toxicities. Thus, induction immunochemotherapy followed by definitive CRT demonstrated encouraging efficacy and tolerable toxicities for unresectable LA-NSCLC.

Keywords

definitive chemoradiotherapy / Induction immunochemotherapy / survival / unresectable LA-NSCLC

References

1	H Sung, J Ferlay, RL Siegel, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2	RS Herbst, D Morgensztern, C Boshoff. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454.
3	SM Yoon, T Shaikh, M Hallman. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20.
4	SJ Antonia, A Villegas, D Daniel, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
5	DS Ettinger, DE Wood, DL Aisner, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497-530.
6	DR Spigel, C Faivre-Finn, JE Gray, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301-1311.
7	Y Wu, Q Zhou, M Chen, et al. OA02.05 Sugemalimab vs placebo after cCRT or sCRT in pts with unresectable stage III NSCLC: final PFS analysis of a phase 3 study. J Thorac Oncol. 2022;17(9):S7-S8.
8	I Cotarla, ML Boron, SL Cullen, et al. Treatment decision drivers in stage III non-small-cell lung cancer: outcomes of a web-based survey of oncologists in the United States. JCO oncology practice. 2020;16(10):e1232-e1242.
9	L Wu, Z Zhang, M Bai, Y Yan, J Yu, Y Xu. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations. Cell Commun Signal. 2023;21(1):119.
10	Q Zhou, M Chen, O Jiang, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209-219.
11	Y Wang, T Zhang, J Wang, et al. Induction immune checkpoint inhibitors and chemotherapy before definitive chemoradiation therapy for patients with bulky unresectable stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023;116(3):590-600.
12	M Provencio, E Nadal, JL Gonzalez-Larriba, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389(6):504-513.
13	PM Forde, J Spicer, S Lu, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973-1985.
14	H Deng, J Liu, X Cai, et al. Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer. Ann Surg. 2022;275(3):e600-e602.
15	JS Ahn, YC Ahn, JH Kim, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666.
16	K Kelly, K Chansky, LE Gaspar, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450-2456.
17	T Eichkorn, F Bozorgmehr, S Regnery, et al. Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer-Cross-sectional study of eligibility and administration rates. Front Oncol. 2020;10:586449.
18	S Senan, A Brade, LH Wang, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962.
19	LA Emens, G Middleton. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-443.
20	KM Heinhuis, W Ros, M Kok, N Steeghs, JH Beijnen, JHM Schellens. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219-235.
21	SK Jabbour, KH Lee, N Frost, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7(9):1-9.
22	M Reck, KH Lee, N Frost, et al. Two-year update from KEYNOTE-799: pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. J Clin Oncol. 2022;40(16):8508.
23	D Marcus, RIY Lieverse, C Klein, et al. Charged particle and conventional radiotherapy: current implications as partner for immunotherapy. Cancers. 2021;13(6):1468.
24	Z Zhang, X Liu, D Chen, J Yu. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258.
25	HJ Ross, DE Kozono, JJ Urbanic, et al. AFT-16: phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15):8513.
26	C Faivre-Finn, D Vicente, T Kurata, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC–an update from the PACIFIC trial. J Thorac Oncol. 2021;16(5):860-867.
27	L Wu, Y Yan, C Zhou, Y Xu. EP08.02-33 Induction immunochemotherapy before definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer. J Thorac Oncol. 2023;18(11):S584.
28	A Thurlapati, LS Dhaliwal, S Chennapragada, et al. Effect of durvalumab in patients with unresectable stage 3 non–small cell lung cancer post-chemoradiotherapy. J Clin Oncol. 2022;40(16):8550.
29	Y Wang, T Zhang, Y Huang, et al. Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2022;112(5):1154-1164.
30	S Peters, E Felip, U Dafni, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133:83-87.
31	American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
32	FC Detterbeck, DJ Boffa, AW Kim, LT Tanoue. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193-203.